Cue Biopharma director granted 21,800 RSUs

Sarraf Pasha reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Sarraf Pasha reported acquisition or exercise transactions in this Form 4 filing.

Cue Biopharma, Inc. director Sarraf Pasha received a grant of 21,800 restricted stock units (RSUs) of common stock. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service. Following this award, Pasha holds 32,595 shares (on a post–1-for-30 reverse split basis effective April 22, 2026).

Insider Trade Summary

Grant/Award: 21,800 shares

Grant/Award 1 txn

Insider Sarraf Pasha

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	21,800	$0.00	$0.00

Holdings After Transaction: Common Stock — 32,595 shares (Direct)

Footnotes (2)

1. F1. Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.
2. F2. Total holdings held after the transaction reflects a 1-for-30 reverse split of the issuer's stock effected on April 22, 2026.

Key Figures

RSUs Granted: 21,800 RSUs Grant Price: $0.0000 per share Holdings After Transaction: 32,595 shares +3 more

6 metrics

RSUs Granted 21,800 RSUs Equity award of restricted stock units to director Sarraf Pasha

Grant Price $0.0000 per share RSUs granted as compensation, not purchased for cash

Holdings After Transaction 32,595 shares Total Cue Biopharma common shares held after the RSU grant

Reverse Split Ratio 1-for-30 Reverse split of Cue Biopharma stock effective April 22, 2026

First Vesting Date July 9, 2027 One-third of RSUs vest on this date, subject to continued service

Final Vesting Date July 9, 2029 Final one-third of RSUs vest on this date, subject to continued service

Key Terms

restricted stock units ("RSUs"), reverse split, vesting

3 terms

restricted stock units ("RSUs") financial

"Represents the grant of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

reverse split financial

"reflects a 1-for-30 reverse split of the issuer's stock"

A reverse split is when a company reduces the number of its outstanding shares by combining several existing shares into one new share, so the price per share rises proportionally while the company’s overall value stays the same. Investors care because it can make a stock appear more respectable or meet exchange rules — like turning many small coins into a single larger bill — but it can also signal financial trouble and often affects trading liquidity and investor perception.

vesting financial

"One-third of the shares subject to the RSUs vest on each of July 9, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cue Biopharma (CUE) director Sarraf Pasha report in this Form 4?

Director Sarraf Pasha reported receiving a grant of 21,800 restricted stock units (RSUs) of Cue Biopharma common stock, with vesting in three equal annual installments starting in July 2027.

How many Cue Biopharma (CUE) shares does Sarraf Pasha hold after this RSU grant?

After the grant, Sarraf Pasha holds 32,595 Cue Biopharma common shares. This total reflects the company’s previously effected 1-for-30 reverse stock split on April 22, 2026.

What are the vesting dates for Sarraf Pasha’s 21,800 Cue Biopharma (CUE) RSUs?

The 21,800 RSUs vest in three equal installments. One-third vests on July 9, 2027, one-third on July 9, 2028, and the final third on July 9, 2029, contingent on continued service.

Was cash paid for the Cue Biopharma (CUE) RSUs granted to Sarraf Pasha?

No purchase price was paid; the RSUs were granted at $0.0000 per share as an equity award, typical for director or employee equity compensation rather than an open-market stock purchase.

How did Cue Biopharma’s reverse split affect Sarraf Pasha’s reported holdings in this Form 4 for CUE?

The reported total of 32,595 shares reflects Cue Biopharma’s 1-for-30 reverse split effective April 22, 2026, meaning prior share amounts were proportionally reduced for reporting consistency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 07:36 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sarraf Pasha

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		A		21,800(1)	A	$0	32,595(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.

2. Total holdings held after the transaction reflects a 1-for-30 reverse split of the issuer's stock effected on April 22, 2026.

	/s/ Michael Meluzio, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)